Tags

Type your tag names separated by a space and hit enter

Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach.
Eur Rev Med Pharmacol Sci. 1999 Jan-Feb; 3(1):27-30.ER

Abstract

The etiology of inflammatory disease is still unknown, but a body of evidence from clinical and experimental observation indicates a role for intestinal microflora in the pathogenesis of this disease. Reduction of microflora using antibiotics, bowel rest and fecal diversion decreases activity in Crohn's disease and in ulcerative colitis. Several trials have been carried out on the use of antibiotic treatment in patients with active ulcerative colitis with contrasting results. A number of trials have been carried out using Rifaximin, a non-absorbable broad-spectrum antibiotic, confirming the absence of systemic bioavalaibility of the drug even when administered at very high doses and for prolonged periods. It may therefore be useful in treatment of ulcerative colitis and pouchitis, since its absorption through inflamed mucosa is negligible, it maintains a topical action without systemic effects and the lack of resistant bacterial strains may allow prolonged and repeated treatments.

Authors+Show Affiliations

Clinica Medica I, Nuove Patologie, Università degli Studi di Bologna.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

10710827

Citation

Gionchetti, P, et al. "Review--antibiotic Treatment in Inflammatory Bowel Disease: Rifaximin, a New Possible Approach." European Review for Medical and Pharmacological Sciences, vol. 3, no. 1, 1999, pp. 27-30.
Gionchetti P, Rizzello F, Venturi A, et al. Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. Eur Rev Med Pharmacol Sci. 1999;3(1):27-30.
Gionchetti, P., Rizzello, F., Venturi, A., Ugolini, F., Rossi, M., Brigidi, P., Johansson, R., Ferrieri, A., Poggioli, G., & Campieri, M. (1999). Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. European Review for Medical and Pharmacological Sciences, 3(1), 27-30.
Gionchetti P, et al. Review--antibiotic Treatment in Inflammatory Bowel Disease: Rifaximin, a New Possible Approach. Eur Rev Med Pharmacol Sci. 1999;3(1):27-30. PubMed PMID: 10710827.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. AU - Gionchetti,P, AU - Rizzello,F, AU - Venturi,A, AU - Ugolini,F, AU - Rossi,M, AU - Brigidi,P, AU - Johansson,R, AU - Ferrieri,A, AU - Poggioli,G, AU - Campieri,M, PY - 2000/3/11/pubmed PY - 2000/3/11/medline PY - 2000/3/11/entrez SP - 27 EP - 30 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 3 IS - 1 N2 - The etiology of inflammatory disease is still unknown, but a body of evidence from clinical and experimental observation indicates a role for intestinal microflora in the pathogenesis of this disease. Reduction of microflora using antibiotics, bowel rest and fecal diversion decreases activity in Crohn's disease and in ulcerative colitis. Several trials have been carried out on the use of antibiotic treatment in patients with active ulcerative colitis with contrasting results. A number of trials have been carried out using Rifaximin, a non-absorbable broad-spectrum antibiotic, confirming the absence of systemic bioavalaibility of the drug even when administered at very high doses and for prolonged periods. It may therefore be useful in treatment of ulcerative colitis and pouchitis, since its absorption through inflamed mucosa is negligible, it maintains a topical action without systemic effects and the lack of resistant bacterial strains may allow prolonged and repeated treatments. SN - 1128-3602 UR - https://www.unboundmedicine.com/medline/citation/10710827/Review__antibiotic_treatment_in_inflammatory_bowel_disease:_rifaximin_a_new_possible_approach_ L2 - https://medlineplus.gov/antibiotics.html DB - PRIME DP - Unbound Medicine ER -